US Graphic Warning Implementation Delayed to 2023

Aug.15.2022
US Graphic Warning Implementation Delayed to 2023
Implementation of US graphic health warnings delayed until October 6, 2023, due to legal challenges and Covid-19.

According to the Winston-Salem Journal, the implementation date for the U.S. graphic health warnings has been postponed by three months to October 6, 2023.


On August 10th, a judge from a Texas regional court approved the latest delay in the release date for the graphic health warnings. This is at least the ninth time a judge has ordered a delay.


The US Food and Drug Administration (FDA) issued a final rule in March 2020 requiring new graphic warnings on cigarette packages. The rule mandates the use of labels featuring lesser-known smoking health risks, such as diabetes, and the warnings must cover the top 50% of both the front and back panels of packages and at least 20% of top advertising space.


In April and May of 2020, cigarette manufacturers and retailers sued the FDA, arguing that the graphic warning requirements were equivalent to government anti-smoking propaganda because the government has never forced legal product manufacturers to use their own ads to spread messages urging adults not to use their products.


In a recent challenge, tobacco companies argued that the deadline delay due to the impact of the COVID-19 pandemic has become too burdensome. They also pointed out that if graphic health warnings are required to be rejected in court again, they face the risk of losing new packaging investments. In March 2021, a regional court in Texas approved the motion by the plaintiffs to postpone the effective date of the final rule until April 14, 2022. This resulted in an additional delay.


Statement:


This article is based on compiled information from a third party and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry exchange and research purposes.


Due to limitations in the compiler's abilities, this article's translation may not be an exact representation of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign issues and stances.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT reported record FY2025 revenue and adjusted operating profit, supported by combustible resilience and accelerating reduced-risk product growth. Heated tobacco volumes surged, led by Ploom. The group confirmed a major three-year RRP investment plan and projected further growth in 2026.
Feb.12
HB 5437 “Vape Safety Act” advances in House committee, proposing statewide licensing for vape shops
HB 5437 “Vape Safety Act” advances in House committee, proposing statewide licensing for vape shops
A committee substitute for House Bill 5437, the Vape Safety Act sponsored by Del. David McCormick (David McCormick), was recommended Monday afternoon by the House Health and Human Resources Committee to the full House, with the bill next heading to the House Judiciary Committee. HB 5437 would require specialty shops selling tobacco, tobacco-derived products, alternative nicotine, or vapor products and accessories to obtain a state license from the Alcohol Beverage Control Administration (ABCA)
Feb.26 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai